Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
08.03. | ALX Oncology (NASDAQ:ALXO) Price Target Cut to $1.50 by Analysts at Stifel Nicolaus | 5 | MarketBeat | ||
07.03. | ALX Oncology (NASDAQ:ALXO) Announces Quarterly Earnings Results, Beats Estimates By $0.17 EPS | 3 | MarketBeat | ||
ALX ONCOLOGY Aktie jetzt für 0€ handeln | |||||
07.03. | Why ALX Oncology Holdings Inc. (ALXO) Soared on Thursday | 1 | Insider Monkey | ||
06.03. | ALX Oncology files $364.12M mixed securities shelf | 1 | Seeking Alpha | ||
06.03. | ALX Oncology GAAP EPS of -$0.55 | 1 | Seeking Alpha | ||
06.03. | ALX ONCOLOGY HOLDINGS INC Q4 Loss Decreases | - | RTTNews | ||
06.03. | ALX ONCOLOGY HOLDINGS INC - 10-K, Annual Report | - | SEC Filings | ||
06.03. | ALX Oncology jumps as Jefferies upgrades on upside potential | 3 | Seeking Alpha | ||
06.03. | Jefferies raises ALX Oncology stock to buy, target to $3 | 2 | Investing.com | ||
05.03. | ALX ONCOLOGY HOLDINGS INC - 8-K, Current Report | - | SEC Filings | ||
05.03. | ALX Oncology Highlights Focused Evorpacept Development Plan, Clinical Progress and Corporate Updates at R&D Day Webcast Event | 15 | GlobeNewswire (USA) | ||
21.02. | ALX Oncology CEO Jason Lettmann verkauft Aktien für 2.483 US-Dollar | 1 | Investing.com Deutsch | ||
21.02. | ALX Oncology-Präsident Jaume Pons verkauft Aktien im Wert von 1.525 US-Dollar | 2 | Investing.com Deutsch | ||
23.01. | ALX Oncology stock falls 16% amid Phase 2 data update | 4 | Seeking Alpha | ||
23.01. | ALX Oncology Presents Positive Updated Data from ASPEN-06 Phase 2 Trial Demonstrating Evorpacept Generates Strong Response and Durable Clinical Benefit in Patients with HER2-Positive Gastric Cancer | 207 | GlobeNewswire (Europe) | Oral presentation at 2025 ASCO Gastrointestinal Cancers Symposium today highlights evorpacept as the first CD47 blocker to show substantial tumor response and a well-tolerated safety profile in a... ► Artikel lesen | |
22.01. | ALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules | 158 | GlobeNewswire (Europe) | SOUTH SAN FRANCISCO, Calif., Jan. 22, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings, Inc. ("ALX Oncology" or the "Company"), (Nasdaq: ALXO), a clinical-stage biotechnology company advancing therapies... ► Artikel lesen | |
22.01. | ALX Oncology appoints new CFO | 1 | Seeking Alpha | ||
22.01. | ALX Oncology Announces Further Additions to Leadership Team and Board of Directors, Appointing Harish Shantharam as Chief Financial Officer and Adding Barbara Klencke and Chris Takimoto to Board of Directors | 1 | GlobeNewswire (USA) | ||
21.01. | ALX Oncology to Host Virtual Company Event Highlighting Updated Data from ASPEN-06 Phase 2 Trial Presented at 2025 ASCO GI | 3 | GlobeNewswire (USA) | ||
17.01. | ALX ONCOLOGY HOLDINGS INC - 8-K, Current Report | - | SEC Filings |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
EVOTEC | 6,125 | +1,07 % | Evotec-Aktie: Crash auf 4 Euro voraus? Behält die Deutsche Bank Recht mit Ihrem Kursziel? | © Foto: Symbolbild von pina messina auf UnsplashKooperationen mit Pharma-Giganten, Hightech-Forschung und trotzdem bewegt sich die Evotec-Aktie nicht richtig nach oben. Die Deutsche Bank warnte vor... ► Artikel lesen | |
MODERNA | 25,250 | -3,66 % | Moderna-Aktie leicht im Minus (29,9070 €) | Der Anteilsschein von Moderna notiert heute ein wenig leichter. Der jüngste Kurs betrug 32,24 US-Dollar. Für der Anteilsschein von Moderna steht gegenwärtig ein Abschlag von 4,13 Prozent zu Buche. Die... ► Artikel lesen | |
NOVAVAX | 5,634 | -4,88 % | Novavax Aktie: Dunkelheit vor dem Sturm? | Der Biotechnologiekonzern verzeichnet erhebliche Kursverluste, setzt jedoch auf die Kooperation mit Sanofi als wichtigen Baustein für zukünftige Ertragsquellen und Kostenoptimierung. Die Novavax-Aktie... ► Artikel lesen | |
CRISPR THERAPEUTICS | 30,900 | -2,52 % | Crispr Therapeutics Aktie: Verliert ihren Kurs? | Der Austritt des operativen Geschäftsführers beim Gentherapie-Unternehmen beunruhigt Investoren und wirft Fragen zur Projektkontinuität im wettbewerbsintensiven Biotech-Sektor auf. Die Finanzmärkte... ► Artikel lesen | |
INOVIO PHARMACEUTICALS | 1,440 | -4,64 % | INOVIO Pharmaceuticals, Inc.: INOVIO Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights | Significant progress toward submitting a biologics license application (BLA) for INO-3107 as a potential treatment for recurrent respiratory papillomatosis (RRP)... ► Artikel lesen | |
INTELLIA THERAPEUTICS | 6,142 | -6,26 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to Nexiguran Ziclumeran (nex-z) for the Treatment of Transthyretin (ATTR) Amyloidosis with ... | CAMBRIDGE, Mass., March 26, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based... ► Artikel lesen | |
EDITAS MEDICINE | 1,059 | -1,72 % | Zacks Research Comments on Editas Medicine FY2027 Earnings | ||
DEFENCE THERAPEUTICS | 0,722 | +4,64 % | Kursraketen und Übernahmefantasie! Steyr Motors, Evotec und Defence Therapeutics! | Steyr Motors reitet jetzt nicht nur die Rüstungs-, sondern auch die Übernahmewelle. Nach der Kooperationsmeldung mit einer Rheinmetall-Tochter ist der Nischenwert zum Shootingstar geworden. Allerdings... ► Artikel lesen | |
BIOMARIN PHARMACEUTICAL | 65,40 | +0,09 % | BioMarin Pharmaceutical Inc.: BioMarin Presents New Data Demonstrating Favorable Safety and Strong Adherence in Real-World Clinical Practice with VOXZOGO (vosoritide) in Children Under 3 with Achondroplasia at 2025 American ... | New data also to be presented for PALYNZIQ® (pegvaliaise-pqpz), reinforcing its value in sustaining blood Phe level reduction and improving health-related quality... ► Artikel lesen | |
PACIFIC BIOSCIENCES OF CALIFORNIA | 1,075 | -1,07 % | PacBio Appoints Jim Gibson As New CFO | WASHINGTON (dpa-AFX) - Life science technology company PacBio, Inc. (PACB) announced Thursday the appointment of Jim Gibson as the company's new Chief Financial Officer, effective as of his... ► Artikel lesen | |
SAREPTA THERAPEUTICS | 57,88 | -1,90 % | Sarepta downgraded at RBC Capital on gene therapy concerns | ||
EXELIXIS | 33,510 | -1,85 % | EXELIXIS, INC. - 8-K, Current Report | ||
NEUROCRINE BIOSCIENCES | 99,72 | -2,00 % | Neurocrine Biosciences: A Smart Biotech Bet With Blockbuster Potential | ||
VAXART | 0,369 | -5,04 % | Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | SOUTH SAN FRANCISCO, Calif., March 27, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) (the "Company" or "Vaxart") today announced that on March 24, 2025, the independent members of the Board... ► Artikel lesen | |
BLUEBIRD BIO | 4,940 | +9,29 % | Gene Therapy-Focused Bluebird Bio Receives Rival Takeover Offer, Stock Jumps |